

Positive preliminary results from the clinical Phase 1 study are presented at a scientific conference

SpectraCure is now conducting a Phase 1 clinical study to treat patients with recurring prostate cancer using the company's photodynamic therapy (PDT) technology. As previously announced, the maximum and final dose of the photosensitising drug has been achieved in the study. Magnetic resonance images (MRI) of prostate taken one week after treatment in the patient so far treated with the highest dose suggests that the treatment had a good detectable therapeutic effect. The images show a clear intended change in the gland and tumour area as a result of the PDT treatment. However, it should be emphasised that the main objective of the Phase 1 study is to demonstrate the safety of the SpectraCure treatment method and to establish the correct dose level. In addition, the preliminary results suggest that the method has the intended therapeutic effect, which is a secondary target for the Phase 1 study.

Johannes Swartling, CTO at SpectraCure, is invited to give a talk about the company's IDOSE technology at a scientific conference organised by the European Society for Photobiology (ESP) in Pisa, Italy, on Friday 8 September. During the lecture, preliminary results from the study will be presented.

The half-hour long talk is titled "Dose Control in interstitial PDT of prostate cancer: clinical experiences" and is about the technology behind IDOSE®: the algorithms that control SpectraCure's treatment planning and the spectroscopic measurements that are the base of the laser light dose control. The lecture is addressed to an audience of PDT experts and researchers and will also touch on the experience of using IDOSE technology in the clinical study.

It should be noted that the results are preliminary. The effect on patients will be continuously evaluated during the further follow-up through PSA tests, an additional magnetic resonance imaging, and tissue biopsies, according to a pre-established protocol.

Link to the conference program:

<http://www.pisa2017.photobiology.eu/sites/default/files/pdfs/Programme.pdf>

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.